Hadley KEY SLIDES 9-5 7:45-8:15 PM

Slides:



Advertisements
Similar presentations
Deriving Biological Inferences From Epidemiologic Studies.
Advertisements

Study Designs in Epidemiologic
Psychological co-morbidity in Diabetes mellitus : assessment and therapy Prof. Dr. Claus Vögele.
Quality of CareResearch Programme > Comorbidity: The aetiological / genetic perspective Martina C. Cornel, professor of community genetics & public health.
Accutane-Psychiatric Disorders A Pharmacoepidemiological Safety Assessment Robert C. Nelson, PhD RCN Associates, Inc. Annapolis, MD.
Estimation and Reporting of Heterogeneity of Treatment Effects in Observational Comparative Effectiveness Research Prepared for: Agency for Healthcare.
Correlation: Relationships Can Be Deceiving. The Impact Outliers Have on Correlation An outlier that is consistent with the trend of the rest of the data.
SOME ADDITIONAL POINTS ON MEASUREMENT ERROR IN EPIDEMIOLOGY Sholom May 28, 2011 Supplement to Prof. Carroll’s talk II.
Dr. Omranifard MD 12 may 2015 Depression is one of the most prevalent psychiatric disorders in late life with devastating health consequences. It could.
Dr. Ed Soltis Department of Neurosciences Spring 2005
Screening for Stroke and Cognitive Impairment Chapter 2: Background.
CHAPTER 24: Converging Issues in Heart Disease, Stroke, and Alzheimer’s Disease in Women.
The Nature of Disease.
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 7: Gathering Evidence for Practice.
Epidemiology The Basics Only… Adapted with permission from a class presentation developed by Dr. Charles Lynch – University of Iowa, Iowa City.
Alzheimer’s Disease Tessa Dillon Nova Southeastern University Clinical Genetics Teri Doolittle, PA-C, MHP, DHSc August 3, 2008.
Kirk Panneton, M.D., FACP George Giokas, M.D. Medical Director, Senior Services Director, Palliative Care CDPHP The Community Hospice September 8, 2012.
Defining Mild Cognitive Impairment Steven T.DeKosky, M.D. Director, Alzheimer’s Disease Research Center University of Pittsburgh Pittsburgh, PA.
POLYCYSTIC OVARY SYNDROME A COMMON FEMALE ENDOCRINE DISEASE SBI4U-01 Mr. Gajewski Bashour Yazji Jason Antrobus Narayan Wagle.
Case(Control)-Free Multi-SNP Combinations in Case-Control Studies Dumitru Brinza and Alexander Zelikovsky Combinatorial Search (CS) for Disease-Association:
EPIDEMIOLOGY Catherine T. Horat RN MSN CS C-FNP NUR 410 Community Focused Nursing.
CHAPTER 23: Neurological Disorders in Women. Introduction Gender differences exist in the development and expression of several neurological disorders,
EXPERIMENTAL EPIDEMIOLOGY
Disability, Frailty and Co-Morbidity L. Fried et al. Gero 302 Jan 2012.
Cognitive Disorders Chapter 13 Nature of Cognitive Disorders: An Overview Perspectives on Cognitive Disorders Cognitive processes such as learning, memory,
Background. Vascular Cognitive Impairment Vascular Cognitive Impairment (VCI) includes the cognitive and behavioural disorders associated with cerebrovascular.
1 Research Methods in Child Psychopathology Carolyn R. Fallahi, Ph. D.
1 Chapter 6: Non-Communicable Diseases. 2 Impact of Non- Communicable Diseases These chronic diseases drive healthcare costs at an alarming annual rate:
Introduction to General Epidemiology (2) By: Dr. Khalid El Tohami.
Health Related Quality of Life after serious occupational injuries and long term disability Presenter: Ibishi Nazmie MD,PhD University Clinical Center.
Methodological quality assessment of observational studies Nicole Vogelzangs Department of Psychiatry & EMGO + institute.
Validity in epidemiological research Deepti Gurdasani.
Characterstic of disease
Scottish National Burden of Disease, Injuries and Risk Factors study:
Some epidemiological principles and methods
Learning objectives Define HIV treatment goals
Module 7.3 Movement Disorders
Associations of Maternal Antidepressant Use During the First Trimester of Pregnancy With Preterm Birth, Small for Gestational Age, Autism Spectrum Disorder,
Introduction.
Modelling Madness Susan Totterdell.
Nanette Safonts Period 3
Circulatory Systems Group
Statistics in Clinical Trials: Key Concepts
MULTIPLE GENES AND QUANTITATIVE TRAITS
Present: Disease Past: Exposure
Methodological Issues and Techniques
PREDICTORS IN DEVELOPMENT OF LEARING DISABILITIES INTRODUCTION-PURPOSE
Neural.
Polypharmacy In Adults: Small Test of Change
Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease that is characterized by persistent respiratory symptoms and.
Reliability and Validity
Etiology of Major Depressive Disorder
11/20/2018 Study Types.
INDIRECT STANDARDIZATION BY MBBSPPT.COM
Chapter 30 Delirium and Dementia
MULTIPLE GENES AND QUANTITATIVE TRAITS
Social & Environmental Determinants Risk & Protective Factors
Summer School on Neuroscience & Aging
Osteoarthritis – a case for personalized health care?
Psychiatric Disorders: Diagnosis to Therapy
Florian T. Merkle, Kevin Eggan  Cell Stem Cell 
Evidence Based Practice
Health Inequalities and Housing
Psychiatric Disorders: Diagnosis to Therapy
Epidemiological Approach
Frailty and Its Effect on the 4 M’s
Myers’ EXPLORING PSYCHOLOGY (6th Ed)
Secondary outcomes in pharmacological and behavioral treatment trials standardized or tailored to intervention type? Kevin M. Gray, M.D. Professor and.
Gender Issues and Addiction
Effect Modifiers.
Presentation transcript:

Hadley KEY SLIDES 9-5 7:45-8:15 PM

endocrinologist

Research Approaches to Multidimensional Aging Problems: Its and Thems Evan Hadley, M.D. Geriatrics and Clinical Gerontology Program National Institute on Aging

Two Perspectives on Contributors to Conditions in Old Age Multiple contributors to a condition A B C D Shared contributor to multiple conditions B C D A

Searching for common contributors: Why bother? B C D For the goal of improving interventions, finding common contributors can help to: Identify better therapeutic targets Decrease polypharmacy (different treatments for B, C, and D) and its potential adverse consequences Increase efficiency or power of clinical trials against B,C, and D: If B+C+D can be considered as an “it”, e.g., a “syndrome” caused by A, this can avoid losses in power due to multiple-comparison adjustments when considering B, C, and D as separate conditions (“them”).

Searching for common causes or contributors One approach: B C D Looking for clustering: Determine whether B, C, and D occur together more often than would be expected by chance. If they do, there is evidence that there may be an “A” Can be done even in absence of “candidate” for A Clustering could occur without any “A”, e.g., B C D

Searching for common causes or contributors B C D ? If evidence of clustering is found, can test relationship of “candidates” for A to outcomes B, C,and D.

Searching for common causes or contributors Another approach: A Candidate etiology: Identify a putative contributor to a group of outcomes.

Searching for common causes or contributors B C D Candidate etiology approach can be done even in absence of a priori evidence for clustering of B, C, and D

Different types of clustering of conditions that could share a common cause or contributory factor Two extremes: Consistent co-occurrence of conditions that are rare individually, e.g., syndromes due to single-gene mutations (Example: Wilson’s Disease) Prima facie case for shared cause is strong Inconsistent co-occurrence of conditions that are common individually, e.g., thinking, moving, feeling problems in old people. Co-occurrence could be due to chance Statistical approaches needed to determine clustering Large number of common conditions in older persons makes this a typical situation in old age

Comorbidities Affect Ascertainment of Clustering Example: Combination of four conditions: Evidence for common underlying cause in 35-year old men? Libido | Muscle Atrophy | Depressive Symptoms | Mild Cognitive Deficits

 Testosterone  Libido | Muscle Atrophy | Depressive Symptoms | Mild Cognitive Deficits Evidence of strong association of the combination of four conditions with a single common causal factor is basis for considering the combination as one condition (hypogonadism), with a single therapeutic target (testosterone level).

Comorbidities Affect Ascertainment of Clustering Example: Combination of these four conditions: Evidence for underlying common cause in 85-year old men?  Libido | Muscle Atrophy | Depressive Symptoms | Mild Cognitive Deficits

Mild Cognitive Deficits Physical inactivity Malnutrition Peripheral vascular disease Et al. Sleep Disorders Social factors Hypothyroidism Early Alzheimer’s Anticholinergic drugs  Testosterone Muscle Atrophy Depressive Symptoms Mild Cognitive Deficits  Libido Depression Some SSRIs Chronic kidney disease Et al. Conditions are common individually, so co-occurrence not rare Each condition has other common potential contributory factors besides low testosterone Only partial overlap of other potential contributory factors to each condition

(pb∩c/pbpc)F+ vs. (pb∩c/pbpc)F- Strategies to Identify Clustering of Conditions and Shared Contributory Factors in the Presence of Multiple Morbidity Statistical techniques to determine clustering – the extent to which a combination of conditions occurs more often than expected by chance, e.g.,using observed/expected ratios (pb∩c/pbpc). If clustering is confined to a small subgroup that has the contributory factor, it may be missed in the overall population. However, role of a “candidate” common contributory factor in a subgroup can be probed by comparing the degree of clustering in the subgroup with the factor with the degree of clustering in the rest of the population, e.g., (pb∩c/pbpc)F+ vs. (pb∩c/pbpc)F-

Candidate etiology approach to identify shared contributory factors: B C D ? ? ?

Candidate etiology approach to identify shared contributory factors: B C D Potential error from observational studies: A is common effect, not common cause. Possible example: cytokines.

Candidate etiology approach to identify shared contributory factors B C D E F Bad effect Good effect Potential problem with pleiotropic factors: Contributory factors to multiple conditions can also protect against other conditions Examples: cytokines, oxygen radicals, various hormones Therapeutic implications, particularly in presence of multiple morbidities or risk factors Therapeutic role for tissue-specific modulators of pleiotropic processes (SERMs, SARMs, et al.)

Contributions of an aging process to multiple conditions can be masked by disease progression and complications Age Primary aging process Early disease process Late stage disease and complications Aging mechanisms may be responsible for starting disease processes whose progression causes new pathologies. The new pathologies can contribute to further progression through mechanisms independent of the original aging mechanism that started the process.

Contributions of an aging process to multiple conditions can be masked by disease progression and complications Age Primary aging process Early disease process Late stage disease and complications Thus, an aging process leading to multiple pathologies in old age may be undetectable in old age if its role in the pathologies is confined to their initiation earlier in life. Implication: Interventions against such an aging process may be ineffective against these pathologies, or even harmful, if started late in life, but effective if started earlier. Some laboratory animal evidence for this phenomenon: caloric restriction, growth hormone.

Life-course approaches to elucidating effects of an aging process on multiple pathologies in old age: Epidemiologic data on relationships of phenotypes and exposures in early and mid-life to co-occurrence of conditions in old age Genetic epidemiologic studies on relationships of genotypes to progression of multiple pathologies over the life span. At what stage(s) does a genotype have its effects? Animal models of effects of genetic factors on co-occurrence of pathologies in old age Animal models of effects of interventions on aging processes in early and mid-life on co-occurrence of conditions in late life